Elena Mikhailovna Kamaltynova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elena Mikhailovna Kamaltynova has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Natal'Ya Viktorovna Shakhova
FSBEI HE ASMU MOH Russia
12 shared publications - Tat'YAna S. Kashinskaya
Altai State Medical University, Barnaul
8 shared publications - Olga Sergeevna Fedorova
Siberian State Medical University
4 shared publications - Liudmila Yur'EVna Barycheva
Stavropol State Medical University; Regional Children’s Clinical Hospital
3 shared publications - Yury Lobanov
Altai State Medical University
3 shared publications - A Yur'EVna Shcherbina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Allergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Open AccessAllergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- 13 April 2026
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 25 (1)
Infantile hemangioma: modern perspectives on pathogenesis and treatment
Infantile hemangioma (IH) is a significant and common interdisciplinary issue in the pediatric population. The etiology of this condition is not fully understood. Several hypotheses exist regarding the origin of IH: the placental hypothesis, genetic mutations, and the influence of external factors. Treatment approaches for IH are diverse and include systemic pharmacotherapy, local treatment, and surgical intervention. Each of these methods has both advantages and limitations, making it impossible to use any single approach as a universal solution for all patients. The beta-blocker propranolol is currently recognized as the first-line medication. The authors of the lecture presented a literature review of modern approaches to selecting treatment for IH, as well as predictors of propranolol efficacy and its possible mechanism of action.
- 13 April 2026
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 25 (1)
Infantile hemangioma: modern perspectives on pathogenesis and treatment
Infantile hemangioma (IH) is a significant and common interdisciplinary issue in the pediatric population. The etiology of this condition is not fully understood. Several hypotheses exist regarding the origin of IH: the placental hypothesis, genetic mutations, and the influence of external factors. Treatment approaches for IH are diverse and include systemic pharmacotherapy, local treatment, and surgical intervention. Each of these methods has both advantages and limitations, making it impossible to use any single approach as a universal solution for all patients. The beta-blocker propranolol is currently recognized as the first-line medication. The authors of the lecture presented a literature review of modern approaches to selecting treatment for IH, as well as predictors of propranolol efficacy and its possible mechanism of action.
- Open Access
- 11 October 2024
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 23 (3) , 116-125
Parameters of leukopoiesis and thrombocytopenia in early urosepsis as potential predictors of a lethal outcome in hospitalized patients
Aim. To perform a comparative analysis of leukopoiesis parameters and platelet count in peripheral blood with evaluation of their changes in the first 48 hours from urosepsis (US) verification in hospitalized patients depending on the outcome of the disease.Materials and methods. A retrospective comparative study included 40 patients with US divided into a group of deceased (n = 10) and a group of recovered (n = 30) individuals. Along with a full clinical and paraclinical examination, which is a routine practice in the urology clinic in case of suspected (confirmed) sepsis, we performed a differentiated assessment of leukopoiesis and platelet count in peripheral blood at baseline (at the moment of US verification) and 48 hours after US verification. The assessment included determination of the immature granulocyte count, investigation of neutrophil granularity intensity (NEUT-GI) and neutrophil reactivity intensity (NEUT-RI), and measurement of the mean platelet volume (MPV).Results. The baseline level of organ dysfunction graded by the SOFA (Sequential Organ Failure Assessment) score was significantly higher in deceased patients than in survivors (6 points vs. 3 points, respectively; p = 0.001). The group of the deceased was characterized by lower platelet and monocyte levels. The ROC analysis with the calculation of area under the curve (AUC) identified the following potential predictors of a lethal outcome in US: proportion of monocytes from the total leukocyte count at baseline ≤ 5.5% (AUC 0.732, p = 0.032), proportion of eosinophils from the total leukocyte count at baseline ≤ 0% (AUC 0.756, p = 0.011), absolute eosinophil count at baseline ≤ 0.01 × 109 / l (AUC 0.802, p = 0.009), absolute basophil count at baseline ≤ 0.03 × 109 / l (AUC 0.718, p = 0.028), NEUT-GI at baseline ≤ 153.2 scatter intensity (SI) units (AUC 0.754, p = 0.021), NEUT-RI at baseline ≤ 59.3 SI units (AUC 0.737, p = 0.024) and their increase after 48 hours by > 0.9 SI units (AUC 0.852, p = 0.001) or by > 1.34% (AUC 0.844, p = 0.003), platelet count at baseline ≤ 144 × 109 / l (AUC 0.762, p = 0.007) and after 48 hours ≤ 174 × 109 / l (AUC 0.769, p < 0.007).Conclusion. The assessment of the platelet count and leukopoiesis parameters, including the ones characterizing neutrophil maturation (NEUT-RI, NEUT-GI), in the first 48 hours from US verification, can be effective predictors of a lethal outcome in patients with US.
- 11 October 2024
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 23 (3) , 116-125
Open AccessParameters of leukopoiesis and thrombocytopenia in early urosepsis as potential predictors of a lethal outcome in hospitalized patients
Aim. To perform a comparative analysis of leukopoiesis parameters and platelet count in peripheral blood with evaluation of their changes in the first 48 hours from urosepsis (US) verification in hospitalized patients depending on the outcome of the disease.Materials and methods. A retrospective comparative study included 40 patients with US divided into a group of deceased (n = 10) and a group of recovered (n = 30) individuals. Along with a full clinical and paraclinical examination, which is a routine practice in the urology clinic in case of suspected (confirmed) sepsis, we performed a differentiated assessment of leukopoiesis and platelet count in peripheral blood at baseline (at the moment of US verification) and 48 hours after US verification. The assessment included determination of the immature granulocyte count, investigation of neutrophil granularity intensity (NEUT-GI) and neutrophil reactivity intensity (NEUT-RI), and measurement of the mean platelet volume (MPV).Results. The baseline level of organ dysfunction graded by the SOFA (Sequential Organ Failure Assessment) score was significantly higher in deceased patients than in survivors (6 points vs. 3 points, respectively; p = 0.001). The group of the deceased was characterized by lower platelet and monocyte levels. The ROC analysis with the calculation of area under the curve (AUC) identified the following potential predictors of a lethal outcome in US: proportion of monocytes from the total leukocyte count at baseline ≤ 5.5% (AUC 0.732, p = 0.032), proportion of eosinophils from the total leukocyte count at baseline ≤ 0% (AUC 0.756, p = 0.011), absolute eosinophil count at baseline ≤ 0.01 × 109 / l (AUC 0.802, p = 0.009), absolute basophil count at baseline ≤ 0.03 × 109 / l (AUC 0.718, p = 0.028), NEUT-GI at baseline ≤ 153.2 scatter intensity (SI) units (AUC 0.754, p = 0.021), NEUT-RI at baseline ≤ 59.3 SI units (AUC 0.737, p = 0.024) and their increase after 48 hours by > 0.9 SI units (AUC 0.852, p = 0.001) or by > 1.34% (AUC 0.844, p = 0.003), platelet count at baseline ≤ 144 × 109 / l (AUC 0.762, p = 0.007) and after 48 hours ≤ 174 × 109 / l (AUC 0.769, p < 0.007).Conclusion. The assessment of the platelet count and leukopoiesis parameters, including the ones characterizing neutrophil maturation (NEUT-RI, NEUT-GI), in the first 48 hours from US verification, can be effective predictors of a lethal outcome in patients with US.
- Open Access
- 13 September 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (4) , 234-240
Severe Antiphospholipid Syndrome in a Child with Chicken Pox: Clinical Case
Background. Antiphospholipid syndrome develops at autoimmune diseases, pregnancy, or genetic predisposition, and it is characterized by high risk of thrombosis in arterial, venous, and capillary vessels. This syndrome in children is rare, and necrotic skin lesions occur in the most extreme cases. Clinical case description. A child, 1 year old, with chicken pox has developed hemorrhagic rash on his back, swelling of the left shoulder and forearm on the 4th day of the disease. Medical treatment included acyclovir, ceftriaxone, sodium heparin. Aggravation of hemorrhagic rash over the body, spread of edema from the left shoulder to upper arm and neck, formation of flaccid bubble and necrosis locus (75 cm) on the outer upper third of the left shoulder were noted on the 5th-6th day. Increase in the levels of antibodies to 2-glycoprotein I (IgG — 48.9 U/ml, IgM — > 100 U/ml) and cardiolipin (IgM — 73.0 U/ml) was revealed. The diagnosis “antiphospholipid syndrome” was established. All necrotized tissues were removed on the 11th day, and the wound defect (86 cm) was subsequently covered by mesh skin grafts. The levels of antibodies (IgG + IgM) to 2-glycoprotein I remained high, 45.2 U/mL, 12 weeks after the onset of the disease. Thus, it has confirmed the development of antiphospholipid syndrome. The child continued treatment with warfarin (3.75 mg/day) with INR control. Conclusion. Hemorrhagic skin lesions in children with infectious diseases requires laboratory diagnostics of antiphospholipid syndrome, early prescription of anticoagulant and antiplatelet therapy, and surgical support.
- 13 September 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (4) , 234-240
Open AccessSevere Antiphospholipid Syndrome in a Child with Chicken Pox: Clinical Case
Background. Antiphospholipid syndrome develops at autoimmune diseases, pregnancy, or genetic predisposition, and it is characterized by high risk of thrombosis in arterial, venous, and capillary vessels. This syndrome in children is rare, and necrotic skin lesions occur in the most extreme cases. Clinical case description. A child, 1 year old, with chicken pox has developed hemorrhagic rash on his back, swelling of the left shoulder and forearm on the 4th day of the disease. Medical treatment included acyclovir, ceftriaxone, sodium heparin. Aggravation of hemorrhagic rash over the body, spread of edema from the left shoulder to upper arm and neck, formation of flaccid bubble and necrosis locus (75 cm) on the outer upper third of the left shoulder were noted on the 5th-6th day. Increase in the levels of antibodies to 2-glycoprotein I (IgG — 48.9 U/ml, IgM — > 100 U/ml) and cardiolipin (IgM — 73.0 U/ml) was revealed. The diagnosis “antiphospholipid syndrome” was established. All necrotized tissues were removed on the 11th day, and the wound defect (86 cm) was subsequently covered by mesh skin grafts. The levels of antibodies (IgG + IgM) to 2-glycoprotein I remained high, 45.2 U/mL, 12 weeks after the onset of the disease. Thus, it has confirmed the development of antiphospholipid syndrome. The child continued treatment with warfarin (3.75 mg/day) with INR control. Conclusion. Hemorrhagic skin lesions in children with infectious diseases requires laboratory diagnostics of antiphospholipid syndrome, early prescription of anticoagulant and antiplatelet therapy, and surgical support.
- 6 April 2023
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 20 (1) , 52-62
Tropomyosins of the helminthes: Sensitization and association with allergic diseases
The increase in the prevalence of allergic diseases has been a driver of the development of new technologies. Over the past two decades, significant progress in biochemistry and molecular allergology has contributed to the study of the structure of allergens and development of component-resolved diagnostics. Specifically, clinically significant families of allergens have been identified, including tropomyosin, which can cause various cross-IgE-mediated reactions. One of the risk factors for sensitization development is helminthiasis, which is common in different regions and population of endemic areas. The global prevalence of helminthiasis remains high. Approximately 1.5 billion people worldwide have chronic infections with at least one helminth. This review aimed to analyze current studies determining the relationship between helminth infections and the development of sensitization to helminth tropomyosin and clinical course of allergic diseases. The analysis of scientific publications described the relationship between helminth tropomyosin and the development of allergic diseases and sensitization in patients with parasitic infection. The PubMed database was used for the review. The review included original articles published between January 1, 2000, and December 31, 2021.
- 6 April 2023
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 20 (1) , 52-62
Tropomyosins of the helminthes: Sensitization and association with allergic diseases
The increase in the prevalence of allergic diseases has been a driver of the development of new technologies. Over the past two decades, significant progress in biochemistry and molecular allergology has contributed to the study of the structure of allergens and development of component-resolved diagnostics. Specifically, clinically significant families of allergens have been identified, including tropomyosin, which can cause various cross-IgE-mediated reactions. One of the risk factors for sensitization development is helminthiasis, which is common in different regions and population of endemic areas. The global prevalence of helminthiasis remains high. Approximately 1.5 billion people worldwide have chronic infections with at least one helminth. This review aimed to analyze current studies determining the relationship between helminth infections and the development of sensitization to helminth tropomyosin and clinical course of allergic diseases. The analysis of scientific publications described the relationship between helminth tropomyosin and the development of allergic diseases and sensitization in patients with parasitic infection. The PubMed database was used for the review. The review included original articles published between January 1, 2000, and December 31, 2021.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 92 (6) , 54-63
Medical and social assessment of the quality of life of a family with a child suffering from food allergy
Медико-социальная оценка качества жизни семьи с ребенком, страдающим пищевой аллергией
- 1 January 2023
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 92 (6) , 54-63
Open AccessMedical and social assessment of the quality of life of a family with a child suffering from food allergy
Медико-социальная оценка качества жизни семьи с ребенком, страдающим пищевой аллергией
- 21 October 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (5)
CLINICAL FEATURES OF THE NEW CORONAVIRUS INFECTION IN CHILDREN
Currently it is about impossible to discuss whether children and adolescents carry the infectious process caused by the SARS-CoV-2 virus only in a mild and asymptomatic form. Ambiguous conclusions can be drawn from the reviewed publications of a number of recent studies in which children and adolescents with complicated course of the new coronavirus infection were under observation. More and more relevant are reports from scientists around the Globe about somatic symptoms that persist after the new coronavirus infection. The purpose of the study was to summarize and analyze the widely available data on the clinical features of the new coronavirus infection in children and adolescents in Russia and worldwide. The bibliographical research was carried out in the reviewed periodicals’ databases as follows: PubMed®, ScienceDirect, Cochrane Library, Google Scholar, eLIBRARY, and CyberLeninka. The keywords for the search were as follows: COVID-19, children, clinical features, clinical symptoms, post COVID syndrome, long-term symptoms after SARS-CoV-2, physical and mental health, new coronavirus infection, clinical manifestations, cognitive impairment. The reviewed period of publications screened: 2020 to 2022 (to date). In total 152 sources were analyzed, from which 60 most representative studies were selected, that in its turn provide data on the clinical features of SARS-CoV-2 in children during different periods of the disease, starting with the onset of the disease in different age groups. Children are as vulnerable to the SARS-CoV-2 infection as adults but more frequently suffer from the disease in mild forms. The main clinical manifestations during the acute period of COVID-19 in children are as follows: fever, respiratory symptoms (rhinorrhea, nasal congestion, cough, shortness of breath), gastrointestinal manifestations (nausea/vomiting, diarrhea), signs of sensory impairment (anosmia, ageusia), arthralgia/myalgia, weakness, fatigue. At the same time the new coronavirus infection can rapidly progress in a severe/life-threatening form in some children that would require intensive care and respiratory support. In addition, the aggravated comorbid background in the anamnesis of severe/critical cases has a significant value. The cardiological and neurological pathology has a special prognostic value as well. A number of publications have proven the indisputable fact of long-term COVID-19 symptoms in children. According to a number of studies more than 70% of those who recovered from COVID-19 complain of one or more symptoms after the end of the acute period of the disease; in some cases, these complaints can persist for up to 10 weeks, and even up to 6 to 7 months after the recovery (in a number of cases described). The prospect for the in-depth study of the course and consequences of COVID-19 in childhood will provide an opportunity to obtain a clear view on the most frequent clinical features of the disease, factors predisposing to the development of severe/critical/life-threatening conditions, and would allow to develop the clear-cut treatment and prevention algorithms.
- 21 October 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (5)
CLINICAL FEATURES OF THE NEW CORONAVIRUS INFECTION IN CHILDREN
Currently it is about impossible to discuss whether children and adolescents carry the infectious process caused by the SARS-CoV-2 virus only in a mild and asymptomatic form. Ambiguous conclusions can be drawn from the reviewed publications of a number of recent studies in which children and adolescents with complicated course of the new coronavirus infection were under observation. More and more relevant are reports from scientists around the Globe about somatic symptoms that persist after the new coronavirus infection. The purpose of the study was to summarize and analyze the widely available data on the clinical features of the new coronavirus infection in children and adolescents in Russia and worldwide. The bibliographical research was carried out in the reviewed periodicals’ databases as follows: PubMed®, ScienceDirect, Cochrane Library, Google Scholar, eLIBRARY, and CyberLeninka. The keywords for the search were as follows: COVID-19, children, clinical features, clinical symptoms, post COVID syndrome, long-term symptoms after SARS-CoV-2, physical and mental health, new coronavirus infection, clinical manifestations, cognitive impairment. The reviewed period of publications screened: 2020 to 2022 (to date). In total 152 sources were analyzed, from which 60 most representative studies were selected, that in its turn provide data on the clinical features of SARS-CoV-2 in children during different periods of the disease, starting with the onset of the disease in different age groups. Children are as vulnerable to the SARS-CoV-2 infection as adults but more frequently suffer from the disease in mild forms. The main clinical manifestations during the acute period of COVID-19 in children are as follows: fever, respiratory symptoms (rhinorrhea, nasal congestion, cough, shortness of breath), gastrointestinal manifestations (nausea/vomiting, diarrhea), signs of sensory impairment (anosmia, ageusia), arthralgia/myalgia, weakness, fatigue. At the same time the new coronavirus infection can rapidly progress in a severe/life-threatening form in some children that would require intensive care and respiratory support. In addition, the aggravated comorbid background in the anamnesis of severe/critical cases has a significant value. The cardiological and neurological pathology has a special prognostic value as well. A number of publications have proven the indisputable fact of long-term COVID-19 symptoms in children. According to a number of studies more than 70% of those who recovered from COVID-19 complain of one or more symptoms after the end of the acute period of the disease; in some cases, these complaints can persist for up to 10 weeks, and even up to 6 to 7 months after the recovery (in a number of cases described). The prospect for the in-depth study of the course and consequences of COVID-19 in childhood will provide an opportunity to obtain a clear view on the most frequent clinical features of the disease, factors predisposing to the development of severe/critical/life-threatening conditions, and would allow to develop the clear-cut treatment and prevention algorithms.
- Open Access
- 4 October 2022
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 21 (4) , 305-310
Prevalence of Vitamin D Insufficiency/Deficiency and Their Role in Atopic Dermatitis Development and Course in Children
Various conclusive evidence on the role of vitamin D in the pathogenesis of atopic dermatitis (AD) has been obtained in recent decades. Many studies have shown that patients with AD have low concentration of 25(OH)D in blood associated with high concentration of allergen specific IgE (according to several reports). The analysis of low 25(OH)D concentration prevalence, association of vitamin D deficiency with AD severity and sensitization to allergens, and association of vitamin D disorders with risk of AD development is presented.
- 4 October 2022
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 21 (4) , 305-310
Open AccessPrevalence of Vitamin D Insufficiency/Deficiency and Their Role in Atopic Dermatitis Development and Course in Children
Various conclusive evidence on the role of vitamin D in the pathogenesis of atopic dermatitis (AD) has been obtained in recent decades. Many studies have shown that patients with AD have low concentration of 25(OH)D in blood associated with high concentration of allergen specific IgE (according to several reports). The analysis of low 25(OH)D concentration prevalence, association of vitamin D deficiency with AD severity and sensitization to allergens, and association of vitamin D disorders with risk of AD development is presented.
- Open Access
- 15 June 2022
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 2
Prevalence of bronchial asthma and allergic diseases among children
Bronchial asthma (BA) and allergic diseases such as allergic rhinitis (AR) and atopic dermatitis (AtD) are the most common chronic diseases, the prevalence of which is growing among the child population with the urbanization and industrialization of society. These diseases place a heavy burden on patients, their families and society as a whole, which is associated with a chronic course, frequent exacerbations and the need for long-term therapy of these diseases. Traditionally, data on the prevalence of BA and allergic diseases among children are based on the results of the program «International Study of Asthma and Allergies in Childhood», focused on school-age children 6–7 and 13–14 years. Standardized international epidemiological studies of the prevalence of BA and allergic diseases in preschool children have not been conducted and to date, few foreign data have been published demonstrating a high prevalence among children of this age. Studies on the epidemiology of asthma and allergic diseases among preschoolers in Russia are few. The purpose of this article is to systematize the currently available information on the prevalence of BA and allergic diseases among children. Data sources: A comprehensive literature search was conducted using the PubMed database.
- 15 June 2022
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 2
Open AccessPrevalence of bronchial asthma and allergic diseases among children
Bronchial asthma (BA) and allergic diseases such as allergic rhinitis (AR) and atopic dermatitis (AtD) are the most common chronic diseases, the prevalence of which is growing among the child population with the urbanization and industrialization of society. These diseases place a heavy burden on patients, their families and society as a whole, which is associated with a chronic course, frequent exacerbations and the need for long-term therapy of these diseases. Traditionally, data on the prevalence of BA and allergic diseases among children are based on the results of the program «International Study of Asthma and Allergies in Childhood», focused on school-age children 6–7 and 13–14 years. Standardized international epidemiological studies of the prevalence of BA and allergic diseases in preschool children have not been conducted and to date, few foreign data have been published demonstrating a high prevalence among children of this age. Studies on the epidemiology of asthma and allergic diseases among preschoolers in Russia are few. The purpose of this article is to systematize the currently available information on the prevalence of BA and allergic diseases among children. Data sources: A comprehensive literature search was conducted using the PubMed database.
- Open Access
- 1 July 2021
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 66 (3) , 70-76
Predictors of bronchial asthma development in preschool children with recurrent broncho-obstructive syndrome
Objective. To study predictors of bronchial asthma development in children of 3-4 years old with recurrent broncho-obstructive syndrome by 5-6 years of age.Material and methods. The authors conducted a prospective cohort study in 2018-2020 with the participation of 61 children aged 3–4 years with recurrent broncho-obstructive syndrome. Inclusion criteria: age 3–4 years; ≥ 3 episodes of broncho-obstructive syndrome in the past 12 months; informed voluntary consent. At the first visit the scientists determined the levels of serum periostin, specific inhalation allergens IgE, total IgE and the number of eosinophils in the blood. In 24 months, at the second visit, bronchial asthma was diagnosed based on the GINA criteria (updated 2019). Binary logistic regression analysis was used to study the predictors of bronchial asthma development.Results. In 24 months from the beginning of the study, bronchial asthma was diagnosed in 29 (47%) children with recurrent broncho-obstructive syndrome. The level of serum periostin and total IgE had no effect on the risk of developing bronchial asthma (p=0,194; p=0,269). According to binary logistic regression, the predictors of bronchial asthma development are burdened family allergic history (odds ratio – OR 3,81; 95% confidence interval – CI 1,14-12,74; p=0,015), allergic rhinitis (OR 4,94; 95% CI 1,37–7,80; p=0,0001), sensitization to the Dermatophagoides pteronyssinus (OR 1,80; 95% CI 1,36–1,13; p=0,045) and eosinophilia (OR 2,10 ; 95% CI 1,23-4,83; p=0,055).Conclusion. A burdened family allergic history, the presence of allergic rhinitis, sensitization to the Dermatophagoides pteronyssinus, eosinophilia are the predictors of bronchial asthma development in children with recurrent broncho-obstructive syndrome by 5-6 years of age.
- 1 July 2021
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 66 (3) , 70-76
Open AccessPredictors of bronchial asthma development in preschool children with recurrent broncho-obstructive syndrome
Objective. To study predictors of bronchial asthma development in children of 3-4 years old with recurrent broncho-obstructive syndrome by 5-6 years of age.Material and methods. The authors conducted a prospective cohort study in 2018-2020 with the participation of 61 children aged 3–4 years with recurrent broncho-obstructive syndrome. Inclusion criteria: age 3–4 years; ≥ 3 episodes of broncho-obstructive syndrome in the past 12 months; informed voluntary consent. At the first visit the scientists determined the levels of serum periostin, specific inhalation allergens IgE, total IgE and the number of eosinophils in the blood. In 24 months, at the second visit, bronchial asthma was diagnosed based on the GINA criteria (updated 2019). Binary logistic regression analysis was used to study the predictors of bronchial asthma development.Results. In 24 months from the beginning of the study, bronchial asthma was diagnosed in 29 (47%) children with recurrent broncho-obstructive syndrome. The level of serum periostin and total IgE had no effect on the risk of developing bronchial asthma (p=0,194; p=0,269). According to binary logistic regression, the predictors of bronchial asthma development are burdened family allergic history (odds ratio – OR 3,81; 95% confidence interval – CI 1,14-12,74; p=0,015), allergic rhinitis (OR 4,94; 95% CI 1,37–7,80; p=0,0001), sensitization to the Dermatophagoides pteronyssinus (OR 1,80; 95% CI 1,36–1,13; p=0,045) and eosinophilia (OR 2,10 ; 95% CI 1,23-4,83; p=0,055).Conclusion. A burdened family allergic history, the presence of allergic rhinitis, sensitization to the Dermatophagoides pteronyssinus, eosinophilia are the predictors of bronchial asthma development in children with recurrent broncho-obstructive syndrome by 5-6 years of age.